SLC5A2 and cancer: From the eight included reviews, 27 point estimates were reported for the risk of any cancer event with SGLT‐2 inhibitors as a class vs placebo and active comparators, including estimates reported for individual SGLT‐2 inhibitor agents (Figure 2).